CD19

Assets acting on this target.

Class
CD19-directed (binds CD19 on B cells)
Pathway
Engineered NK cells recognize and eliminate CD19-expressing B cells implicated in autoimmune disease

CD19 is a transmembrane glycoprotein expressed across almost the entire B-lymphocyte lineage, from early progenitor cells through mature B cells, though it is largely absent from terminally differentiated plasma cells. Because B cells are central to antibody-mediated autoimmune disease (producing pathogenic autoantibodies, presenting antigens to T cells, and secreting inflammatory cytokines), eliminating CD19-expressing cells offers a way to interrupt these pathogenic circuits. Chimeric antigen receptor (CAR) technology can redirect immune effector cells to recognize CD19 and destroy the cells bearing it. This targeting logic, first developed for cancer using a patient's own T cells, can also be applied to autoimmune disease and paired with natural killer (NK) cells, cytotoxic lymphocytes that mediate rapid target-cell killing without requiring prior antigen sensitization. Using allogeneic NK cells sourced from healthy donors rather than autologous T cells allows for 'off-the-shelf' manufacturing, avoiding the delays associated with individualized cell collection and engineering. This mechanism broadly matters wherever pathogenic B cells sustain autoimmune disease, including conditions in which conventional immunosuppression or antibody-based B cell depletion has proven inadequate.

By indication

Related mechanisms

CD19 drugs compared

17 drugs, stage by indication
17 drugs acting on CD19: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
InebilizumabAmgen, Hansoh Pharmaceutical Group, Tanabe Pharma Corporationmonoclonal antibodyApprovedApproved in Generalized Myasthenia Gravis; Phase 2 in Systemic Lupus Erythematosus
obecabtagene autoleucelAucatzylAutolus Therapeutics plcCAR-T cell therapyApprovedApproved in Acute Lymphoblastic Leukemia
TafasitamabBeijing InnoCare Pharma Tech Co., Incyte, Xencormonoclonal antibodyApprovedApproved in Diffuse Large B-Cell Lymphoma; Approved in Follicular Lymphoma; Approved in Large B-Cell Lymphoma
budoprutugClimb Bio, Inc.monoclonal antibodyPhase 2Phase 2 in Primary Membranous Nephropathy; Phase 1/2 in Systemic Lupus Erythematosus
cemacabtagene ansegedleucelAllogene Therapeutics, Inc.cell therapyPhase 2Phase 2 in Large B-Cell Lymphoma
FT819Fate TherapeuticsCAR-T cell therapyPhase 2Phase 2 in Systemic Lupus Erythematosus
Rapcabtagene autoleucelNovartisundisclosedPhase 2Phase 2 in Lupus Nephritis
Beijing Biotech anti-CD19 CAR-TBeijing BiotechCAR-T cell therapyPhase 1/2Phase 1/2 in Systemic Lupus Erythematosus
Zugocabtagene geleucelCRISPR TherapeuticsCAR-TPhase 1/2Phase 1/2 in Follicular Lymphoma; Phase 1 in Systemic Lupus Erythematosus
ABBV-319AbbVieantibody-drug conjugatePhase 1Phase 1 in Rheumatoid Arthritis; Phase 1 in Sjögren's Disease; Phase 1 in Systemic Lupus Erythematosus
ABBV-519AbbVieNot recordedPhase 1Phase 1 in Rheumatoid Arthritis; Phase 1 in Systemic Lupus Erythematosus
Azercabtagene zapreleucelImugene Limited, PRECISION BIOSCIENCES INC, TG THERAPEUTICS, INC.cell therapyPhase 1Not recorded
IC19 CAR-TBeijing Immunochina Medical Science & Technology Co., Ltd.CAR-T cell therapyPhase 1Phase 1 in Systemic Lupus Erythematosus
UTAA09PersonGen BioTherapeutics (Suzhou) Co., Ltd.CAR-T cell therapyPhase 1Phase 1 in Systemic Lupus Erythematosus
ZM001Beijing Immunochina Medical Science & Technology Co., Ltd.CAR-TPhase 1Phase 1 in Systemic Lupus Erythematosus
ABBV-619AbbVieundisclosedStage not recordedNot recorded
FT522Fate Therapeuticscell therapyStage not recordedNot recorded

← all mechanisms